{"denoms":[{"counts":[{"groupId":"BG000","value":"20"}],"units":"Participants"}],"groups":[{"description":"Patients received oral lithium carbonate once or twice daily. Treatment continued for up to 8 weeks in the absence of disease progression or unacceptable toxicity.","id":"BG000","title":"Treated Patients"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"22","upperLimit":"63","value":"49.5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"19"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"14"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Non-Hodgkin lymphoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Acute myeloid leukemia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Multiple myeloma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Chronic myeloid leukemia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Acute lymphoid leukemia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Myelodysplastic syndrome"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Aplastic anemia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Paroxysmal nocturnal hemoglobinuria"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Chronic lymphocytic leukemia"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Indication for transplantation","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"Myeloablative"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Nonmyeloablative"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Type of pretransplant conditioning regimen","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Cyclosporine and mycophenolate mofetil (MMF)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"Tacrolimus and methotrexate"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Cyclophosphamide, tacrolimus, MMF"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Tacrolimus and mycophenolate mofeftil"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Graft-versus-host disease (GVHD) prophylaxis regimen","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Duodenum alone"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Colon alone"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Duodenum and colon"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Mucosal denudation","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Tacrolimus"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Cyclosporine"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Mycophenolate mofetil"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Agents given to prevent GVHD at the time of enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Infliximab"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Rabbit anti-thymocyte globulin"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Horse anti-thymocyte globulin"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Extracorporeal photopheresis"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Mesenchymal stem cells"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Mycophenolate mofetil"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Tacrolimus"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Sirolimus"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Cyclosporine"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Agents given to treat GVHD more than 3 days before enrollment in the study","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"22","upperLimit":"215","value":"90"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Interval from transplantation to start of study product administration","unitOfMeasure":"days"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Methotrexate"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Pentostatin"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Rabbit anti-thymocyte globulin"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Mycophenolate mofetil"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Infliximab"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Alemtuzumab"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Agents given to treat GVHD within 3 days before or after enrollment","unitOfMeasure":"Participants"}]}